慢性疼痛治療の世界市場：市場規模・シェア分析 - 動向、促進要因、競合情勢、将来予測 (2024年～2030年)

市場概要

世界の慢性疼痛治療市場は、2023年に976億米ドルの収益を達成し、2024年から2030年にかけて7.4%のCAGRを記録し、2030年には1,596億米ドルに達すると予測されています。業界発展の主な理由としては、こうしたソリューションに対する政府の支援の拡大、高齢者人口の増加、慢性的な健康状態の発生率の上昇などが挙げられます。

主な洞察

重度の頭痛、腰痛、顔面痛などの慢性疼痛が増加していることから、医薬品カテゴリーが約7.7%のCAGRで成長し、業界シェアをリードすると予測されています。

2023年には、線維筋痛症、変形性関節症、関節リウマチなどの筋骨格系疾患の発生が多いため、筋骨格系カテゴリのシェアは40%でした。

米国では2019～2021年に、5,320万人もの成人が上記の疾患：異なる種類の関節炎 (関節リウマチを含む)、痛風、狼瘡または線維筋痛症に罹患しています。

筋骨格系分野は、関節炎有病率の増加や世界中で障害の原因となっている腰痛がトップであるなどの要因により、予測期間終了までCAGR 7.3%と予測されます。

適応症別では予測期間中、がん性疼痛カテゴリーが8.0%のCAGRで成長すると予測されます。

地域別ではアジア太平洋地域が、医療インフラの進歩、可処分所得の増加、高齢者人口の増加、慢性疼痛の蔓延に後押しされ、予測期間中のCAGRは7.8%と最も急成長します。

2023年には、北米地域が業界シェアの55%を占め、発達した医療インフラ、高い医療費、高度な疼痛治療ソリューションの広範な入手可能性から有利な立場に立っています。

当レポートでは、世界の慢性疼痛治療の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、セグメント別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：適応症別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：流通チャネル別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：適応症別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：流通チャネル別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：適応症別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：流通チャネル別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Eli Lilly and Company
• GlaxoSmithKline plc
• Pfizer Inc.
• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Novartis AG
• Johnson & Johnson Services Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Becton, Dickinson and Company
• Sanofi S.A.
• Teva Pharmaceutical Industries Limited
• AbbVie Inc.
• Paradigm Biopharmaceuticals Limited

第31章 付録

Market Overview

The chronic pain treatment market achieved a revenue of USD 97.6 billion in 2023 and is projected to experience a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030, reaching USD 159.6 billion by 2030. The major reasons accountable for the development of the industry include the growing government backing for these solutions, increasing elderly populace, and rising occurrence of chronic health conditions.

The industry players have been constantly spending in emerging innovative items for chronic pain treatment. Wearable tech for the treatment of long-lasting pain is one of the major improvements in the chronic pain treatment industry.

The World Health Organization projects a substantial surge in the worldwide populace aged 60 and more from 12% to 22% between 2015 and 2050. This demographic move has augmented the occurrence of chronic pain, mainly among elder patients in nursing homes, posing a challenge for care facilities.

To confront this problem, a combination of pharmacological, non-pharmacological (physical and occupational therapies), and occupational therapies is employed, positively impacting the chronic pain treatment market.

Chronic illnesses such as sickle-cell anemia, osteoarthritis, fibromyalgia, cancer, and autoimmune illnesses such as rheumatoid arthritis are dominant worldwide, requiring therapeutic interventions for better pain management. The extensive use of treatments such as physiotherapy, medication, and psychological therapy reflects the rising load of chronic diseases and their impact on healthcare systems globally.

Key Insights

The drugs category is projected to advance at a CAGR of around 7.7% and lead the industry share because of increasing chronic pain cases such as severe headaches, lower back pain, and facial pain.

Reasons contributing to this development include the growing worldwide elderly populace, sedentary lifestyles, and an increase in surgical procedures.

The need for painkillers is projected to intensify in response to these trends over the forecast period.

In 2023, the musculoskeletal category had a 40% industry share because of the high occurrence of musculoskeletal illnesses such as fibromyalgia, osteoarthritis, and rheumatoid arthritis.

In 2019-2021, as many as 53.2 million U.S. adults had these conditions: different kinds of arthritis (including rheumatoid arthritis), gout, lupus or fibromyalgia, according to NHIS (National Health Interview Survey).

Musculoskeletal segment is predicted to have a CAGR of 7.3% until the end of the forecast period due to some factors e.g. increase arthritis prevalence and back pain which is responsible for disability all over the world being at the top.

During the projection period, the cancer pain category is projected to advance at a CAGR of 8.0% based on indication.

The National Cancer Institute classifies cancer as a principal worldwide reason of death, with forecasts indicating increasing new cases and demises by 2040.

Growing cancer survivor numbers contribute to industry development because of the long-lasting and commonly severe pain related with the disease.

The APAC region is set to be the fastest-growing industry with a CAGR of 7.8% during the projection period, propelled by advancing healthcare infrastructure, increasing disposable income, rising elderly populace, and growing chronic pain prevalence.

Asia's elderly populace is projected to double from 395 million in 2019 to 587 million by 2030, paying to advanced demand for pain treatment medications and devices.

In 2023, the North American region, holding a 55% industry share, advantages from developed healthcare infrastructure, high healthcare spending, and extensive obtainability of advanced pain treatment solutions.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by indication
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by distribution channel
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Indication (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by Distribution Channel (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Indication (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by Distribution Channel (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Indication (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by Distribution Channel (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Indication (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by Distribution Channel (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Indication (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by Distribution Channel (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Indication (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by Distribution Channel (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Indication (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by Distribution Channel (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Indication (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by Distribution Channel (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Indication (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by Distribution Channel (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Indication (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by Distribution Channel (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Indication (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by Distribution Channel (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Indication (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by Distribution Channel (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Indication (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by Distribution Channel (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Indication (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by Distribution Channel (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Indication (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by Distribution Channel (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Indication (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by Distribution Channel (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Indication (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by Distribution Channel (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Indication (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by Distribution Channel (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Indication (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by Distribution Channel (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Indication (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by Distribution Channel (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Indication (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by Distribution Channel (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Indication (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by Distribution Channel (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Indication (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by Distribution Channel (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Eli Lilly and Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. GlaxoSmithKline plc
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Pfizer Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Medtronic plc
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abbott Laboratories
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Boston Scientific Corporation
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Novartis AG
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Johnson & Johnson Services Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. AstraZeneca PLC
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Bristol-Myers Squibb Company
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Becton, Dickinson and Company
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary
• 30.12. Sanofi S.A.
  • 30.12.1. Business overview
  • 30.12.2. Product and service offerings
  • 30.12.3. Key financial summary
• 30.13. Teva Pharmaceutical Industries Limited
  • 30.13.1. Business overview
  • 30.13.2. Product and service offerings
  • 30.13.3. Key financial summary
• 30.14. AbbVie Inc.
  • 30.14.1. Business overview
  • 30.14.2. Product and service offerings
  • 30.14.3. Key financial summary
• 30.15. Paradigm Biopharmaceuticals Limited
  • 30.15.1. Business overview
  • 30.15.2. Product and service offerings
  • 30.15.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports